Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Terminated · Phase 2 · NCT04524689
Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
At a glance
- Research payments reported, 2025
- $49,441
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 57
About the trial
- Sponsor
- Sanofi
- Tested
- SAR408701 (Tusamitamab ravtansine) (drug), Pembrolizumab (drug), Cisplatin (drug), Carboplatin (drug), Pemetrexed (drug)
- Dates
- Started 2020-10-26; completion 2024-12-24
- Results posted
- Yes
Primary Objective: * Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed to be tested in the expansion part of the study in the NSQ NSCLC population * Expansion part (including participants treated at the recommended dose for expansion \[RDE\] from the Safety Run-in part): to assess the antitumor activity of several dose levels (DLs; if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of several DLs of tusamitamab ravtansine in combination with pembrol…
From ClinicalTrials.gov, last updated 2025-10-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $49,441 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Kansas Medical Center Research Inst Inc $49,441
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.